A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

PURPOSE: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors. EXPERIMENTAL DESIGN: Twenty-seven pediatric patients with recurrent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Osenga, Kaci L., Hank, Jacquelyn A., Albertini, Mark R., Gan, Jacek, Sternberg, Adam G., Eickhoff, Jens, Seeger, Robert C., Matthay, Katherine K., Reynolds, C. Patrick, Twist, Clare, Krailo, Mark, Adamson, Peter C., Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2006
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2587020/
https://ncbi.nlm.nih.gov/pubmed/16551859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-05-2000
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados